NASDAQ:SAVA Cassava Sciences (SAVA) Stock Price, News & Analysis $14.92 +2.17 (+17.02%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$12.86▼$14.9450-Day Range$9.57▼$23.1252-Week Range$8.79▼$32.10Volume3.65 million shsAverage Volume1.34 million shsMarket Capitalization$715.86 millionP/E RatioN/ADividend YieldN/APrice Target$131.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Cassava Sciences alerts: Email Address Cassava Sciences MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside778.0% Upside$131.00 Price TargetShort InterestBearish33.62% of Shares Sold ShortDividend StrengthN/ASustainability-0.82Upright™ Environmental ScoreNews Sentiment0.10Based on 11 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.86) to $1.63 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.31 out of 5 starsMedical Sector343rd out of 936 stocksPharmaceutical Preparations Industry159th out of 436 stocks 3.0 Analyst's Opinion Consensus RatingCassava Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCassava Sciences has only been the subject of 1 research reports in the past 90 days.Read more about Cassava Sciences' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted33.62% of the outstanding shares of Cassava Sciences have been sold short.Short Interest Ratio / Days to CoverCassava Sciences has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in Cassava Sciences has recently increased by 23.22%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCassava Sciences does not currently pay a dividend.Dividend GrowthCassava Sciences does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCassava Sciences has received a 74.60% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for Alzheimer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Cassava Sciences is -0.82. Previous Next 2.8 News and Social Media Coverage News SentimentCassava Sciences has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Cassava Sciences this week, compared to 5 articles on an average week.Search Interest65 people have searched for SAVA on MarketBeat in the last 30 days. This is an increase of 59% compared to the previous 30 days.MarketBeat Follows22 people have added Cassava Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cassava Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.00% of the stock of Cassava Sciences is held by insiders.Percentage Held by InstitutionsOnly 38.05% of the stock of Cassava Sciences is held by institutions.Read more about Cassava Sciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cassava Sciences are expected to grow in the coming year, from ($1.86) to $1.63 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cassava Sciences is -6.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cassava Sciences is -6.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCassava Sciences has a P/B Ratio of 4.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cassava Sciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Cassava Sciences Stock (NASDAQ:SAVA)Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.Read More SAVA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SAVA Stock News HeadlinesJuly 24 at 11:42 AM | msn.comBuy Aehr Test Systems, Sell Cassava SciencesJuly 24 at 3:44 AM | seekingalpha.comCassava Sciences: Turning The Corner Into A Brick WallJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 23 at 5:42 PM | benzinga.comCassava Sciences Advances Alzheimer's Drug Through High-Stakes Phase 3 TrialsJuly 22, 2024 | investorplace.comSAVA Stock Alert: Cassava Sciences Pops on Late-Stage Trial UpdateJuly 22, 2024 | fool.comWhy Cassava Sciences Stock Is Skyrocketing TodayJuly 21, 2024 | americanbankingnews.comCassava Sciences (NASDAQ:SAVA) Trading Up 3.5%July 20, 2024 | americanbankingnews.comCassava Sciences (NASDAQ:SAVA) Earns "Neutral" Rating from HC WainwrightJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 19, 2024 | marketwatch.comCassava Sciences CEO, Chairman Remi Barbier ResignsJuly 19, 2024 | msn.comCassava Sciences Faces Leadership Shake-Up, Prioritizes Transparency And Scientific Rigor In Alzheimer's TrialsJuly 19, 2024 | msn.comCassava Sciences stock tumbles as CEO Remi Barbier resignsJuly 19, 2024 | nytimes.comExecutives Depart Cassava, Maker of Disputed Alzheimer’s DrugJuly 17, 2024 | investorplace.comSAVA Stock Plunges as Cassava Sciences CEO Steps Down. What to Know.July 17, 2024 | globenewswire.comCassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other InitiativesJuly 8, 2024 | investorplace.com3 Healthcare Stocks to Sell in July Before They Crash & BurnJuly 5, 2024 | investorplace.com3 Biotech Stocks to Sell in July Before They Crash & BurnJuly 2, 2024 | seekingalpha.comCassava Sciences: A 'Moon Shot' Becomes A Bigger 'Long Shot'See More Headlines Receive SAVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today7/26/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SAVA CUSIPN/A CIK1069530 Webwww.cassavasciences.com Phone(512) 501-2444Fax512-501-0414Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$131.00 High Stock Price Target$131.00 Low Stock Price Target$131.00 Potential Upside/Downside+778.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-97,220,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-66.08% Return on Assets-53.72% Debt Debt-to-Equity RatioN/A Current Ratio1.74 Quick Ratio1.74 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.26 per share Price / Book4.58Miscellaneous Outstanding Shares47,980,000Free Float43,658,000Market Cap$715.86 million OptionableOptionable Beta-0.57 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Remi Barbier (Age 64)Founder, Chairman, President & CEO Comp: $1.2MMr. Eric J. Schoen (Age 56)Chief Financial Officer Comp: $460kMr. R. Christopher Cook (Age 60)Senior VP, Company Secretary & General Counsel Comp: $425kDr. James W. Kupiec M.D. (Age 71)Chief Medical Officer Comp: $435kDr. George Thornton Ph.D.Senior Vice President of TechnologyMr. Michael ZamlootSenior Vice President of Technical OperationsDr. Michael Marsman Pharm.D.Senior Vice President of Regulatory AffairsDr. Lindsay H. Burns Ph.D.Senior Vice President of NeuroscienceMore ExecutivesKey CompetitorsVerrica PharmaceuticalsNASDAQ:VRCANature's Sunshine ProductsNASDAQ:NATRscPharmaceuticalsNASDAQ:SCPHVerastemNASDAQ:VSTMChimerixNASDAQ:CMRXView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 21,558 shares on 7/26/2024Ownership: 0.294%Clear Creek Financial Management LLCBought 7,025 shares on 7/25/2024Ownership: 0.303%Essex LLCBought 4,644 shares on 7/23/2024Ownership: 0.115%Brookstone Capital ManagementBought 1,000 shares on 7/18/2024Ownership: 0.037%Walleye Trading LLCBought 34,500 shares on 5/17/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions SAVA Stock Analysis - Frequently Asked Questions How have SAVA shares performed this year? Cassava Sciences' stock was trading at $22.51 on January 1st, 2024. Since then, SAVA stock has decreased by 33.7% and is now trading at $14.92. View the best growth stocks for 2024 here. How were Cassava Sciences' earnings last quarter? Cassava Sciences, Inc. (NASDAQ:SAVA) released its quarterly earnings results on Friday, May, 10th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by $0.90. When did Cassava Sciences' stock split? Shares of Cassava Sciences split on Thursday, December 21st 2023. The 14-10 split was announced on Thursday, December 21st 2023. The newly minted shares were payable to shareholders after the closing bell on Thursday, December 21st 2023. An investor that had 100 shares of stock prior to the split would have 140 shares after the split. Who are Cassava Sciences' major shareholders? Top institutional investors of Cassava Sciences include Clear Creek Financial Management LLC (0.30%), Bank of New York Mellon Corp (0.29%), Essex LLC (0.12%) and Brookstone Capital Management (0.04%). Insiders that own company stock include Eric Schoen and James William Kupiec. View institutional ownership trends. How do I buy shares of Cassava Sciences? Shares of SAVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cassava Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cassava Sciences investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Novavax (NVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), NIO (NIO) and DURECT (DRRX). This page (NASDAQ:SAVA) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cassava Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cassava Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
